Free Trial
NASDAQ:AKLI

Akili (AKLI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.43
$0.43
50-Day Range
$0.42
$0.44
52-Week Range
$0.19
$1.25
Volume
N/A
Average Volume
2.20 million shs
Market Capitalization
$34.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AKLI stock logo

About Akili Stock (NASDAQ:AKLI)

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

AKLI Stock News Headlines

Biden's Successor: The Radical Threat to YOUR Savings!
Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.
War on Elon Escalates…
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
Akili to be delisted after getting acquired
Why Is Akili (AKLI) Stock Up 68% Today?
See More Headlines
Receive AKLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akili and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/11/2023
Today
9/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:AKLI
Fax
N/A
Employees
130
Year Founded
N/A

Profitability

Net Income
$-59,490,000.00
Net Margins
-2,492.04%
Pretax Margin
-2,489.32%

Debt

Sales & Book Value

Annual Sales
$1.95 million
Book Value
$0.75 per share

Miscellaneous

Free Float
70,776,000
Market Cap
$34.01 million
Optionable
Optionable
Beta
1.72
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Walter Edward Martucci II (Age 41)
    Ph.D., Co-Founder & Chairman
    Comp: $759.1k
  • Mr. Matthew Franklin M.B.A. (Age 50)
    President, CEO & Director
    Comp: $639.13k
  • Dr. Adam Gazzaley M.D. (Age 54)
    Ph.D., Co-Founder, Chief Science Advisor & Director
    Comp: $126.45k
  • Ms. Jacqueline L. Studer J.D. (Age 65)
    Chief Legal Officer, General Counsel & Secretary
    Comp: $559.55k
  • Ms. Caty Reid
    VP of Marketing & Communications
  • Dr. Scott H. Kollins Ph.D.
    Chief Medical Officer
  • Mr. Jonathan David (Age 46)
    Chief Product Officer

AKLI Stock Analysis - Frequently Asked Questions

How were Akili's earnings last quarter?

Akili, Inc. (NASDAQ:AKLI) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.04. The firm earned $0.11 million during the quarter. Akili had a negative trailing twelve-month return on equity of 79.93% and a negative net margin of 2,492.04%.

Who are Akili's major shareholders?

Top institutional shareholders of Akili include Renaissance Technologies LLC (0.16%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Walter Edward Martucci II, Matthew Franklin, Jacqueline Studer and Santosh Shanbhag.
View institutional ownership trends
.

This page (NASDAQ:AKLI) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners